JNJ-86974680

DRUG2 trials

Sponsors

Johnson & Johnson Enterprise Innovation Inc., Janssen Research & Development, LLC

Conditions

Carcinoma, Non-small-Cell LungProstatic Neoplasms

Phase 1

A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer

RecruitingNCT06116786

Johnson & Johnson Enterprise Innovation Inc.Carcinoma, Non-small-Cell Lung

Start: 2023-11-27End: 2029-06-07Target: 126Updated: 2026-03-13

A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer

RecruitingNCT07319871

Janssen Research & Development, LLCProstatic Neoplasms

Start: 2026-01-14End: 2027-04-30Target: 40Updated: 2026-03-13

Related Papers

Abstract CT137: Initial results from a phase 1 study of an A2a receptor antagonist, administered as monotherapy and in combination with anti-PD1 therapy in patients with advanced non-small cell lung cancer

Cancer Research2025-04-25